Introduction to Commentaries on the Use of Placebo-Controlled Trials of New Therapies in the Treatment of Type 2 Diabetes
- Regenstrief Institute, Indiana University Medical Center, Indianapolis, Indiana
As the editor in chief of Diabetes Care, I was stimulated by the thoughtful letter of David S.H. Bell (1) questioning the value and ethics of placebo-controlled trials in the development of new therapeutic agents for the treatment of hyperglycemia in type 2 diabetes, and I decided to look into this issue more in depth. I asked three people to give their perspectives on this issue. The first response, …
